These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38451784)

  • 1. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.
    Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
    Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
    Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
    Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism.
    Trézéguet V; Fatrouni H; Merched AJ
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.
    Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
    Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells.
    Nawas AF; Solmonson A; Gao B; DeBerardinis RJ; Minna JD; Conacci-Sorrell M; Mendelson CR
    Cell Commun Signal; 2023 Nov; 21(1):331. PubMed ID: 37985999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
    Wu C; Spector SA; Theodoropoulos G; Nguyen DJM; Kim EY; Garcia A; Savaraj N; Lim DC; Paul A; Feun LG; Bickerdike M; Wangpaichitr M
    Cancer Metab; 2023 May; 11(1):7. PubMed ID: 37226257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
    Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
    Front Immunol; 2020; 11():55. PubMed ID: 32117235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tryptophan and its metabolites in normal physiology and cancer etiology.
    Perez-Castro L; Garcia R; Venkateswaran N; Barnes S; Conacci-Sorrell M
    FEBS J; 2023 Jan; 290(1):7-27. PubMed ID: 34687129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
    Li F; Zhao Z; Zhang Z; Zhang Y; Guan W
    BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
    Sari S; Tomek P; Leung E; Reynisson J
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
    Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
    Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells.
    Pham QT; Taniyama D; Akabane S; Takashima T; Maruyama R; Sekino Y; Sentani K; Yasui W; Oue N
    Pathobiology; 2023; 90(1):44-55. PubMed ID: 35679834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of targeting tryptophan catabolism in cancer.
    Opitz CA; Somarribas Patterson LF; Mohapatra SR; Dewi DL; Sadik A; Platten M; Trump S
    Br J Cancer; 2020 Jan; 122(1):30-44. PubMed ID: 31819194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma.
    Bickerdike MJ; Nafia I; Bessede A; Chen CB; Wangpaichitr M
    BMC Cancer; 2024 Jul; 24(1):889. PubMed ID: 39048947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Deficiency of Indoleamine 2,3-dioxygenase Aggravates Vascular but Not Liver Disease in a Nonalcoholic Steatohepatitis and Atherosclerosis Comorbidity Model.
    Arora A; Tripodi GL; Kareinen I; Berg M; Forteza MJ; Gisterå A; Griepke S; Casagrande FB; Martins JO; Abdalla DSP; Cole J; Monaco C; Ketelhuth DFJ
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity.
    Kuo LW; Crump LS; O'Neill K; Williams MM; Christenson JL; Spoelstra NS; Roy MK; Argabright A; Reisz JA; D'Alessandro A; Boorgula MP; Goodspeed A; Bickerdike M; Bitler BG; Richer JK
    Cancer Res Commun; 2024 Oct; 4(10):2699-2713. PubMed ID: 39311710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma.
    Mohapatra SR; Sadik A; Tykocinski LO; Dietze J; Poschet G; Heiland I; Opitz CA
    Front Immunol; 2019; 10():2762. PubMed ID: 31866995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.